The performance of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial surge of copyright, fueled by Viagra's unprecedented popularity, generated substantial wealth , the expiry in key territories has introduced considerable volatility. Investors are now facing the effect of rival medications